AbbVie 3Q Global Skyrizi Revenue $5.78B, Up 22.7% >ABBV

What happened

AbbVie reported third-quarter global revenue for Skyrizi of $5.78 billion. This represents a 22.7% increase compared with the same period in the prior year.

Confirmed

Global impact / market context

Skyrizi is a major medicine for AbbVie, so faster sales growth can lift total company revenue and help offset weaker sales elsewhere. Investors watch this because rising product sales can support profit and cash available for research and dividends.

Analyst inference

A 22.7% sales jump suggests strong demand for Skyrizi, which is important as AbbVie faces competition and patent losses on older drugs. Continued growth of newer medicines can shape investor expectations for future revenue and capital spending.

Analyst inference

What to watch

1. Watch whether AbbVie reports total company revenue and profit alongside this Skyrizi figure, since those details were not included in the supplied article. Confirmed
2. AbbVie could face pressure to keep Skyrizi growing quickly if competitors launch similar treatments, which may affect future revenue and marketing costs. Proposed
3. If Skyrizi sales keep rising at a similar pace, investors may expect stronger total revenue and more cash available, which could influence spending plans. Analyst inference

Evidence

• Original source link unavailable